Article

Aspheric ablation: good for hyperopic presbyopes

Aspheric ablation is a good surgical option for enhancing near vision in hyperopic presbyopes.

Aspheric ablation is a good surgical option for enhancing near vision in hyperopic presbyopes, according to Marc Lafontaine and colleagues from the Canadian multicentre LASIK trial of aspheric treatments for the correction of hyperopic presbyopia.

A total of 93 hyperopic presbyopic eyes that underwent aspheric ablation were included in the study and used as the basis for predictive factors. Mean preoperative sphere was 1.67 D and the mean cylinder was 0.43 D. Pre- and postoperative subjective questionnaires were handed-out to each subject.

All patients achieved simultaneous 20/25 distance vision and J3 vision at 12-months follow-up. Patient satisfaction was good and spectacle independence was achieved and maintained in more than half of subjects.

Predictive factors of good outcomes include patients requiring glasses for distance vision preoperatively, hyperopic refractive error to appreciate a three line or more improvement and three to six months for neural adaptation to realise the benefit of correction.

The study found that aspheric ablation is a good surgical option for enhancing near vision in hyperopic presbyopes and that patient selection is a key factor in predicting good refractive outcomes and satisfaction.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.